Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 03/20/2026 | PUT | $2.50 | 2,072 | +30 | +1.47% |
| 02/20/2026 | CALL | $25.00 | 16 | +1 | +6.67% |
| 02/20/2026 | CALL | $30.00 | 22 | +1 | +4.76% |
| 03/20/2026 | CALL | $35.00 | 362 | +1 | +0.28% |
| 04/17/2026 | CALL | $35.00 | 1,195 | +1 | +0.08% |
| 02/20/2026 | CALL | $7.50 | 0 | 0 | |
| 07/17/2026 | PUT | $20.00 | 1 | 0 | |
| 07/17/2026 | PUT | $22.50 | 30 | 0 | |
| 07/17/2026 | PUT | $25.00 | 0 | 0 | |
| 07/17/2026 | PUT | $30.00 | 0 | 0 | |
| 07/17/2026 | PUT | $35.00 | 0 | 0 | |
| 04/17/2026 | CALL | $22.50 | 3,277 | -25 | -0.76% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026
01/12 11:35 am
Benzinga
Read moreArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer
12/22 09:00 am
GlobeNewswire Inc.
Read moreImmunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
12/16 02:17 pm
Benzinga
Read moreArriVent Posts Wider Loss in Fiscal Q2
08/11 08:11 am
The Motley Fool
Read moreArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
07/01 11:15 pm
GlobeNewswire Inc.
Read moreArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study
06/23 07:00 am
GlobeNewswire Inc.
Read moreArriVent Announces a Multi-Target ADC Collaboration with Alphamab
06/05 07:00 am
GlobeNewswire Inc.
Read moreArriVent Appoints John Hohneker, M.D., to its Board of Directors
05/16 04:05 pm
GlobeNewswire Inc.
Read moreArriVent Appoints Kristine Peterson to its Board of Directors
04/22 04:05 pm
GlobeNewswire Inc.
Read moreArriVent BioPharma Reports Full Year 2023 Financial Results
03/28 04:05 pm
GlobeNewswire Inc.
Read more$10M Bet On ArriVent BioPharma? Check Out These 4 Stocks Insiders Are Buying
02/02 09:56 am
Benzinga
Read more